Launch of the Cleveland Clinic CHIP Clinic: Applying Genomic Discovery to Cardiology
Krishna Aragam, Director of Cardiovascular Genomics at Cleveland Clinic, reposted Ohad Oren’s post on LinkedIn:
“Great to see the launch of the Cleveland Clinic Clonal Hematopoiesis of Indeterminate Potential (CHIP) Cardiology Clinic, a new frontier for applying genomic discoveries to cardiovascular medicine.
CHIP represents a powerful example of how genomic variation — in this case somatic (acquired later in life) rather than germline (inherited at birth) — can inform personalized cardiovascular risk and management.
Looking forward to working with Ohad Oren, MD, MPH and the team to advance precision cardiovascular care guided by genomic insights at the Cleveland Clinic Heart, Vascular and Thoracic Institute.”
Quoting Ohad Oren’s post:
“Launching the Cleveland Clinic CHIP Cardiology Clinic, an exciting step toward integrating clonal hematopoiesis into cardiovascular care.
Excited to share my Circulation paper with Dr. Peter Libby, outlining our vision for the growth and development of CHIP Cardiology programs”
Title: Incorporating Management of Clonal Hematopoiesis of Indeterminate Potential Into Cardiovascular Practice
Authors: Ohad Oren, Peter Libby

Stay informed with Hemostasis Today.
-
Aug 26, 2026, 16:53Chokri Ben Lamine: Antiphospholipid Syndrome After Kidney Transplantation
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal